JP2019529509A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529509A5
JP2019529509A5 JP2019518050A JP2019518050A JP2019529509A5 JP 2019529509 A5 JP2019529509 A5 JP 2019529509A5 JP 2019518050 A JP2019518050 A JP 2019518050A JP 2019518050 A JP2019518050 A JP 2019518050A JP 2019529509 A5 JP2019529509 A5 JP 2019529509A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
alk4
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019518050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529509A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/055199 external-priority patent/WO2018067740A1/en
Publication of JP2019529509A publication Critical patent/JP2019529509A/ja
Publication of JP2019529509A5 publication Critical patent/JP2019529509A5/ja
Priority to JP2022034076A priority Critical patent/JP2022084709A/ja
Priority to JP2024174115A priority patent/JP2025004103A/ja
Pending legal-status Critical Current

Links

JP2019518050A 2016-10-05 2017-10-04 腎臓疾患を治療するための組成物および方法 Pending JP2019529509A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022034076A JP2022084709A (ja) 2016-10-05 2022-03-07 腎臓疾患を治療するための組成物および方法
JP2024174115A JP2025004103A (ja) 2016-10-05 2024-10-03 腎臓疾患を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404603P 2016-10-05 2016-10-05
US62/404,603 2016-10-05
PCT/US2017/055199 WO2018067740A1 (en) 2016-10-05 2017-10-04 Compositions and method for treating kidney disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022034076A Division JP2022084709A (ja) 2016-10-05 2022-03-07 腎臓疾患を治療するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2019529509A JP2019529509A (ja) 2019-10-17
JP2019529509A5 true JP2019529509A5 (https=) 2020-11-12

Family

ID=61831201

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019518050A Pending JP2019529509A (ja) 2016-10-05 2017-10-04 腎臓疾患を治療するための組成物および方法
JP2022034076A Pending JP2022084709A (ja) 2016-10-05 2022-03-07 腎臓疾患を治療するための組成物および方法
JP2024174115A Pending JP2025004103A (ja) 2016-10-05 2024-10-03 腎臓疾患を治療するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022034076A Pending JP2022084709A (ja) 2016-10-05 2022-03-07 腎臓疾患を治療するための組成物および方法
JP2024174115A Pending JP2025004103A (ja) 2016-10-05 2024-10-03 腎臓疾患を治療するための組成物および方法

Country Status (7)

Country Link
US (1) US11976111B2 (https=)
EP (2) EP4026556B1 (https=)
JP (3) JP2019529509A (https=)
CN (2) CN116650622A (https=)
AU (1) AU2017340504A1 (https=)
CA (1) CA3039074A1 (https=)
WO (1) WO2018067740A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110430890B (zh) 2016-11-10 2024-09-10 科乐斯疗法公司 激活素受体iia型变体及其使用方法
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
JP7405772B2 (ja) 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンiia型受容体変異体および同変異体を含む医薬組成物
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
CN110538323A (zh) * 2019-09-29 2019-12-06 南京鼓楼医院 抗lcn2抗体在制备治疗狼疮性肾炎的药物中的应用
WO2021183819A1 (en) * 2020-03-13 2021-09-16 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2022076634A1 (en) 2020-10-08 2022-04-14 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
CN113384684A (zh) * 2021-06-04 2021-09-14 四川大学华西医院 Bmp2沉默改善肾草酸钙结石损伤的机制的应用
US20240366722A1 (en) * 2021-08-16 2024-11-07 Acceleron Pharma Inc. Compositions and methods for treating renal diseases or conditions
CN118903377B (zh) * 2024-07-01 2025-05-27 南方医科大学顺德医院(佛山市顺德区第一人民医院) Lcn2蛋白在制备治疗血管钙化药物中的应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6011577A (en) 1997-06-30 2000-01-04 Polaroid Corporation Modular optical print head assembly
US6372454B2 (en) 1997-08-29 2002-04-16 Human Genome Sciences, Inc. Nucleic acid molecules encoding Follistatin-3
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU772694B2 (en) 1999-01-21 2004-05-06 Metamorphix International, Inc. Growth differentiation factor inhibitors and uses therefor
DE60042021D1 (de) 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2005025601A1 (en) 2003-09-15 2005-03-24 Monash University Follistatin isoforms and uses thereof
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-p-셀렉틴 항체
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
JP5766179B2 (ja) * 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
KR20180085825A (ko) 2009-08-13 2018-07-27 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
NZ707477A (en) * 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
MX388380B (es) * 2014-04-18 2025-03-19 Acceleron Pharma Inc Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
CN107428818A (zh) * 2015-01-29 2017-12-01 密西根州立大学校董会 隐藏多肽及其用途
US10227392B2 (en) * 2015-04-06 2019-03-12 Acceleron Pharma Inc. ALK7:ActRIIB heteromultimers and uses thereof
MA41919A (fr) * 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations

Similar Documents

Publication Publication Date Title
JP2019529509A5 (https=)
JP2025004103A5 (https=)
JP2018516240A5 (https=)
AU2019232838B2 (en) Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage
RU2559532C2 (ru) Антагонисты рецептора и лигандов alk1 и их применение
JP2019536438A5 (https=)
JP2024038040A5 (https=)
US8642031B2 (en) Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
PT1871667E (pt) Sistema de lavagem móvel de motores nas asas e de recuperação de água
CN110678195A (zh) ALK4:ActRIIB异多聚体及其用途
JP2015119705A (ja) 新規な形態の二重標的抗体およびその使用
WO2004019866A2 (en) Compositions and methods for treating cardiovascular disease
PT1804835E (pt) Construções multiméricas
KR20140123558A (ko) Alk1 길항제 및 신세포 암종 치료에서의 그의 용도
CA2724525A1 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
US10059756B2 (en) Compositions comprising ALK1-ECD protein
EP2377888A1 (en) Fusion protein
WO2011093082A1 (ja) 変形性関節症治療剤または予防剤を製造するための使用
AU2018279010B2 (en) ALK1 receptor and ligand antagonists and uses thereof
AU2014200003A1 (en) ALK1 receptor and ligand antagonists and uses thereof
WO2011093081A1 (ja) 変形性関節症治療剤を含有する注射剤